IL-2-activated haploidentical NK cells restore NKG2D- mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA

European Journal of Immunology

Volumn 40, Issue 11, 2010, Pages 3255-3267

  Kloess, Stephan ^a   Huenecke, Sabine ^a   Piechulek, Daniel ^a   Esser, Ruth ^a   Koch, Joachim ^b   Brehm, Claudia ^a   Soerensen, Jan ^a   Gardlowski, Tanja ^a   Brinkmann, Andrea ^a   Bader, Peter ^a   Passweg, Jakob ^c   Klingebiel, Thomas ^a   Schwabe, Dirk ^a   Koehl, Ulrike ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Cytotoxicity; Nk cells; Nkg2d; Smica; Tumor escape mechanisms

Indexed keywords

INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D; SOLUBLE MHC CLASS I CHAIN RELATED GENE A; UNCLASSIFIED DRUG; HLA ANTIGEN CLASS 1; IL2 PROTEIN, HUMAN; KLRK1 PROTEIN, HUMAN; MHC CLASS I RELATED CHAIN A; MHC CLASS I-RELATED CHAIN A; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER IMMUNOLOGY; CASE REPORT; CHILD; CONTROLLED STUDY; HAPLOIDY; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NEUROBLASTOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ADOLESCENT; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; BLOOD; CANCER STAGING; CELLULAR IMMUNITY; FEMALE; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; LIVING DONOR; LYMPHOKINE ACTIVATED KILLER CELL; MALE; METABOLISM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRESCHOOL CHILD; STEM CELL TRANSPLANTATION; TUMOR ESCAPE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LIVING DONORS; LYMPHOCYTE ACTIVATION; MALE; MONITORING, IMMUNOLOGIC; NEOPLASM STAGING; NEUROBLASTOMA; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TUMOR ESCAPE;

EID: 79952109621     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201040568     Document Type: Article

References (45)

1. Trinchieri, G., Biology of natural killer cells. Adv. Immunol. 1989. 47: 187-376.
2. Biron, C. A., Activation and function of natural killer cell responses during viral infections. Curr. Opin. Immunol. 1997. 9: 24-34.
3. Prigione, I., Corrias, M. V., Airoldi, I., Raffaghello, L., Morandi, F., Bocca, P., Cocco, C. et al., Immunogenicity of human neuroblastoma. Ann N Y Acad Sci, 2004. 1028: 69-80.
4. Koehl, U., Sorensen, J., Esser, R., Zimmermann, S., Gruttner, H. P., Tonn, T., Seidl, J. et al., IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol. Dis. 2004. 33: 261-266.
5. Koehl, U., Esser, R., Zimmermann, S., Tonn, T., Kotchetkov, R., Bartling, T., Sorensen, J. et al., Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin. Padiatr. 2005. 217: 345-350.
6. Passweg, J. R., Tichelli, A., Meyer-Monard, S., Heim, D., Stern, M., Kuhne, T., Favre, G. et al., Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004. 18: 1835-1838.
7. Rubnitz, J. E., Inaba, H., Ribeiro, R. C., Pounds, S., Rooney, B., Bell, T., Pui, C. H. et al., NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J. Clin. Oncol. 2010. 28: 955-959.
8. Sivori, S., Vitale, M., Morelli, L., Sanseverino, L., Augugliaro, R., Bottino, C., Moretta, L. et al., p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J. Exp. Med. 1997. 186: 1129-1136.
9. Pessino, A., Sivori, S., Bottino, C., Malaspina, A., Morelli, L., Moretta, L., Biassoni, R. et al., Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J. Exp. Med. 1998. 188: 953-960.
10. Vitale, M., Bottino, C., Sivori, S., Sanseverino, L., Castriconi, R., Marcenaro, E., Augugliaro, R. et al., NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J. Exp. Med. 1998. 187: 2065-2072.
11. Cantoni, C., Bottino, C., Vitale, M., Pessino, A., Augugliaro, R., Malaspina, A., Parolini, S. et al., NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J. Exp. Med. 1999. 189: 787-796.
12. Pende, D., Parolini, S., Pessino, A., Sivori, S., Augugliaro, R., Morelli, L., Marcenaro, E. et al., Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J. Exp. Med. 1999. 190: 1505-1516.
13. Moretta, A., Biassoni, R., Bottino, C., Mingari, M. C. and Moretta, L., Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol. Today 2000. 21: 228-234.
14. Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L. and Spies, T., Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999. 285: 727-729.
15. Wu, J., Song, Y., Bakker, A. B., Bauer, S., Spies, T., Lanier, L. L. and Phillips, J. H., An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999. 285: 730-732.
16. Pende, D., Cantoni, C., Rivera, P., Vitale, M., Castriconi, R., Marcenaro, S., Nanni, M. et al., Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur. J. Immunol. 2001. 31: 1076-1086.
17. Diermayr, S., Himmelreich, H., Durovic, B., Mathys-Schneeberger, A., Siegler, U., Langenkamp, U., Hofsteenge, J. et al., NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 2008. 111: 1428-1436.
18. Boissel, N., Rea, D., Tieng, V., Dulphy, N., Brun, M., Cayuela, J. M., Rousselot, P. et al., BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J. Immunol. 2006. 176: 5108-5116.
19. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. and Schreiber, R. D., Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002. 3: 991-998.
20. Khong, H. T. and Restifo, N. P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 2002. 3: 999-1005.
21. Rabinovich, G. A., Gabrilovich, D. and Sotomayor, E. M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 2007. 25: 267-296.
22. Zwirner, N. W., Fuertes, M. B., Girart, M. V., Domaica, C. I. and Rossi, L. E. et al., Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system. Cytokine Growth Factor Rev. 2007. 18: 159-170.
23. Groh, V., Wu, J., Yee, C. and Spies, T., Tumor-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002. 419: 734-738.
24. Salih, H. R., Rammensee, H. G. and Steinle, A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J. Immunol. 2002. 169: 4098-4102.
25. Pende, D., Rivera, P., Marcenaro, S., Chang, C. C., Biassoni, R., Conte, R., Kubin, M. et al., Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 2002. 62: 6178-6186.
26. Groh, V., Smythe, K., Dai, Z. and Spies, T., Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nat. Immunol. 2006. 7: 755-762.
27. Cinatl, J., Mainke, M., Weissflog, A., Rabenau, H., Kornhuber, B., and Doerr, H. W., In vitro differentiation of human neuroblastoma cells induced by sodium phenylacetate. Cancer Lett. 1993. 70: 15-24.
28. Kloss, S., Bochennek, K., Huenecke, S., Zimmermann, S. Y., Kuci, S., Muller, T., Wels, W. S. et al., A novel five-colour flow cytometric assay to determine NK cell cytotoxicity against neuroblastoma and other adherent tumor cells. J. Immunol. Methods 2007. 325: 140-147.
29. Huenecke, S., Zimmermann, S. Y., Kloess, S., Esser, R., Brinkmann, A., Tramsen, L., Koenig, M. et al., IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion. J. Immunother. 2010. 33: 200-210.
30. Fernandez, N. C., Lozier, A., Flament, C., Ricciardi-Castagnoli, P., Bellet, D., Suter, M., Perricaudet, M. et al., Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. 1999. 5: 405-411.
31. Zimmermann, S. Y., Esser, R., Rohrbach, E., Klingebiel, T. and Koehl, U., A novel four-colour flow cytometric assay to determine natural killer cell or T-cell-mediated cellular cytotoxicity against leukaemic cells in peripheral or bone marrow specimens containing greater than 20% of normal cells. J. Immunol. Methods 2005. 296: 63-76.
32. Walzer, T., Dalod, M., Robbins, S. H., Zitvogel, L. and Vivier, E., Natural-killer cells and dendritic cells: "l'union fait la force". Blood 2005. 106: 2252-2258.
33. Lou, Z., Jevremovic, D., Billadeau, D. D. and Leibson, P. J., A balance between positive and negative signals in cytotoxic lymphocytes regulates the polarization of lipid rafts during the development of cell-mediated killing. J. Exp. Med. 2000. 191: 347-354.
34. Seliger, B., Abken, H. and Ferrone, S. HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends Immunol. 2003. 24: 82-87.
35. Benlahrech, A., Harris, J., Meiser, A., Papagatsias, T., Hornig, J., Hayes, P., Lieber, A., Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc. Natl. Acad. Sci. USA 2009. 106: 19940-19945.
36. Kloss, M., Decker, P., Baltz, K. M., Baessler, T., Jung, G., Rammensee, H. G., Steinle, A. et al., Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA. J. Immunol. 2008. 181: 6711-6719.
37. Groh, V., Rhinehart, R., Secrist, H., Bauer, S., Grabstein, K. H. and Spies, T. et al., Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc. Natl. Acad. Sci. USA 1999. 96: 6879-6884.
38. Raffaghello, L., Prigione, I., Airoldi, I., Camoriano, M., Levreri, I., Gambini, C., Pende, D. et al., Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004. 6: 558-568.
39. Ostberg, J. R., Dayanc, B. E., Yuan, M., Oflazoglu, E. and Repasky, E. A., Enhancement of natural killer (NK) cell cytotoxicity by fever-range thermal stress is dependent on NKG2D function and is associated with plasma membrane NKG2D clustering and increased expression of MICA on target cells. J. Leukoc. Biol. 2007. 82: 1322-1331.
40. Fuertes, M. B., Girart, M. V., Molinero, L. L., Domaica, C. I., Rossi, L. E., Barrio, M. M., Mordoh, J. et al., Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J. Immunol. 2008. 180: 4606-4614.
41. Jinushi, M., Takehara, T., Tatsumi, T., Yamaguchi, S., Sakamori, R., Hiramatsu, N., Kanto, T. et al., Natural killer cell and hepatic cell interaction via NKG2A leads to dendritic cell-mediated induction of CD4 CD25 T cells with PD-1-dependent regulatory activities. Immunology 2007. 120: 73-82.
42. Dulphy, N., Haas, P., Busson, M., Belhadj, S., Peffault de Latour, R., Robin, M. et al., An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation. J. Immunol. 2008. 181: 2227-2237.
43. Dasgupta, S., Bhattacharya-Chatterjee, M., O'Malley, B. W., Jr. and Chatterjee, S. K., Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer. J. Immunol. 2005. 175: 5541-5550.
44. Jinushi, M., Takehara, T., Tatsumi, T., Hiramatsu, N., Sakamori, R., Yamaguchi, S., and Hayashi, N., Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J. Hepatol. 2005. 43: 1013-1020.
45. Trotta, R., Col, J. D., Yu, J., Ciarlariello, D., Thomas, B., Zhang, X., Allard, J. 2nd, TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J. Immunol. 2008. 181: 3784-3792.